Patent intelligence · US
US 6680211
Fluorescent nanocrystal-embedded microspheres for fluorescence analysis
Fluorescent nanocrystal-embedded microspheres for fluorescence analysis
Patent details — US 6680211
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jan 20, 2004
- Expiration
- Jan 15, 2024
- Applicant
- BioCrystal, Ltd.
- Claims
- 27
- CPC classes
- A61K, A61K9/167
Quick answer
US 6680211 (Fluorescent nanocrystal-embedded microspheres for fluorescence analysis) is held by BioCrystal, Ltd.. Status: expired. Granted Jan 20, 2004. Expires Jan 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioCrystal, Ltd.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K9/167
More from BioCrystal, Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12162838
Human plasma kallikrein inhibitors
granted -
US 12121503
Antiviral treatments
granted -
US 12116346
Human plasma kallikrein inhibitors
granted -
US 12054492
Imidazole-containing inhibitors of ALK2 kinase
granted -
US 12043610
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted -
US 11975003
Methods and compositions for treatment of Zika virus infection
granted -
US 11866418
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted
Frequently asked questions
What is US patent 6680211?
US 6680211 (Fluorescent nanocrystal-embedded microspheres for fluorescence analysis) is held by BioCrystal, Ltd.. Status: expired. Granted Jan 20, 2004. Expires Jan 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6680211?
BioCrystal, Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 6680211 expire?
Our index shows an expiration date of Jan 15, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.